Radicava (edaravone): Take Action for Access

In October 2018, a new ALS treatment called Radicava was approved by Health Canada. It’s one of only two treatment options available to people living with this terminal disease. Today, over a year later, Radicava is still not available to Canadians through public drug plans. We want to change that. Join us in advocating for […]

Is the loss of normal function of C9ORF72 protein in a particular cell type a key driver of ALS disease processes?

Rahul Kumar has a burning curiosity to uncover the biological mechanisms driving neurodegenerative diseases. After finishing his combined Bachelor of Science/Master of Science degrees at a prestigious research institute in India, he moved to Canada so he could work on ALS research. He joined Dr. Peter McPherson’s lab at the Montreal Neurological Institute and Hospital […]

Top 10 Research Stories of 2019

2020 is shaping up to be another exciting year in ALS research discovery. Last year, major scientific advances in Canada and internationally led to significant and exciting progress in ALS research. As identified by the ALS Canada Research team, here are the most newsworthy research stories of 2019 that provide hope for what’s to come. […]

What is the role of a newly discovered protein in ALS?

Myriam Gagné was not expecting to work on ALS research. But the first time she saw Dr. Christine Vande Velde’s lab at l’Université de Montréal, it was “love at first sight.” Studying ALS would allow her to combine basic cell biology, neurosciences and biochemistry, her main academic areas of interest. She joined the lab in […]

Is an experimental drug that can prevent abnormal protein behaviour in ALS already out there?

When Marc Shenouda first learned about ALS as an undergraduate science student, he found himself asking many questions: Why is the average life expectancy only two to five years after diagnosis? Why is there is no cure yet? How can we find better treatments, ones that could extend life by more than a few months? […]